¼¼°èÀÇ ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀå : À¯Çüº°, ´Ü°èº°, Ä¡·á¹ýº°, ¸ð´Þ¸®Æ¼º°, µô¸®¹ö¸® ¸ðµ¨º° - ¿¹Ãø(-2030³â)
Clinical Trial Services Market by Type (Laboratory, Monitoring, Recruitment, PV, Data Management), Phase (I, II, III), Therapy (Oncology, Neurology, Dermatology, CVD), Modality (Biologics, Devices), Delivery Model (FSP, Hybrid) - Global Forecast to 2030
»óǰÄÚµå : 1682826
¸®¼­Ä¡»ç : MarketsandMarkets
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 522 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 7,162,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,650 £Ü 9,621,000
PDF (5-user License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,150 £Ü 11,792,000
PDF (Corporate License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÀÌ¿ë Àοø¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, ±¹³»¿¡ ÀÖ´Â »ç¾÷À常 ÇØ´çµÇ¸ç, ÇØ¿Ü ÁöÁ¡ µîÀº Æ÷ÇÔµÇÁö ¾Ê½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,469,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. (100% ÀÚȸ»ç´Â µ¿ÀÏ ±â¾÷À¸·Î °£Áֵ˴ϴÙ.) Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀå ±Ô¸ð´Â 2025³â 665¾ï 9,000¸¸ ´Þ·¯¿¡¼­ 2030³â 1,018¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ 8.9%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¦¾à, ¹ÙÀÌ¿À, ÀÇ·á±â±â ±â¾÷µéÀÌ ÀÓ»ó ¿¬±¸ Ȱµ¿À» CRO(ÀÓ»ó½ÃÇè¼öʱâ°ü)¿¡ ¾Æ¿ô¼Ò½ÌÇÏ´Â »ç·Ê°¡ Áõ°¡ÇÔ¿¡ µû¶ó CRO°¡ Á¦°øÇÏ´Â ±â´ÉÀû ¼­ºñ½º Á¦°ø¾÷ü(FSP), ÇÏÀ̺긮µå ¼­ºñ½º Á¦°ø ¸ðµ¨°ú °°Àº À¯¿¬ÇÑ ¼­ºñ½º ¸ðµ¨ÀÌ ½ÃÀåÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. À¯¿¬ÇÑ ¼­ºñ½º ¸ðµ¨Àº ±â¾÷ÀÌ Áß¿äÇÑ ¾÷¹«¸¦ ÅëÁ¦Çϸ鼭 ºñ¿ë °ü¸®¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ºÐ»êÇü ¸ðµ¨, ¿þ¾î·¯ºí ±â±â, µðÁöÅÐ Ç÷§ÆûÀ» Ȱ¿ëÇÏ¿© ȯÀÚ Âü¿©¿Í À¯Áö¸¦ °­È­Çϴ ȯÀÚ Á᫐ ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, AI¿Í ¸®¾ó¿ùµå µ¥ÀÌÅÍ(RWD) µîÀÇ ±â¼ú ¹ßÀüÀ¸·Î ÀÓ»ó½ÃÇèÀÇ È¿À²¼º, ½Ã¼³ ¼±Á¤, ȯÀÚ ¸ðÁýÀÌ ÃÖÀûÈ­µÇ°í ÀÖ½À´Ï´Ù. ÃÖÀûÈ­µÇ°í ÀÖ½À´Ï´Ù. °³ÀÎÈ­µÈ ÀÇ·á¿Í Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î Ç¥ÀûÄ¡·á¿¡ ÃÊÁ¡À» ¸ÂÃá ÀÓ»ó½ÃÇèÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, CRO´Â º¹ÀâÇÑ ÀÓ»ó½ÃÇè ¼³°è¸¦ Áö¿øÇØ¾ß ÇÕ´Ï´Ù. ±ÔÁ¦ ±â°üÀº ¼Ò¾Æ ÀÓ»ó½ÃÇèÀ» Áß½ÃÇϰí ÀÖÀ¸¸ç, CRO´Â Àü¹® Áö½ÄÀ» ½ÀµæÇÒ Çʿ䰡 ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÓ»ó½ÃÇèÀÇ ´Ù¾ç¼ºÀ» Àå·ÁÇÏ´Â FDAÀÇ °¡À̵å¶óÀÎÀº CRO°¡ ȯÀÚ ¸ðÁýÀ» È®´ëÇÏ°í ´õ Æø³ÐÀº ´ëÇ¥¼ºÀ» È®º¸ÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ¼¼Æ÷Ä¡·á, À¯ÀüÀÚÄ¡·á, »ý¹°ÇÐÀû Á¦Á¦, RNA¸¦ ÀÌ¿ëÇÑ Ä¡·á µî ½Å¾à ÆÄÀÌÇÁ¶óÀÎ Áõ°¡´Â Àü¹®ÀûÀÎ Àӻ󿬱¸ ¼­ºñ½ºÀÇ Çʿ伺À» ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù.

Á¶»ç ¹üÀ§
Á¶»ç ´ë»ó ¿¬µµ 2024-2030³â
±âÁØ ¿¬µµ 2024³â
¿¹Ãø ±â°£ 2024-2030³â
´ÜÀ§ 10¾ï ´Þ·¯
ºÎ¹® ´Ü°è, ¼­ºñ½º À¯Çü, Ä¡·á ¿µ¿ª, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ª
´ë»ó Áö¿ª ºÏ¹Ì À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ±âŸ Áö¿ª

"Ä¡·á ¿µ¿ªº°·Î´Â Á¾¾ç Ä¡·á ¿µ¿ªÀÌ ¿¹Ãø ±â°£ µ¿¾È ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù."

2024³â ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀå Áß Á¾¾ç Ä¡·á ºÐ¾ß°¡ Ä¡·á ºÐ¾ßº°·Î °¡Àå Å« ½ÃÀåÀ» Â÷ÁöÇß½À´Ï´Ù. Àü ¼¼°è ¼ö¸¹Àº ¾Ï ȯÀÚ¿Í »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ Çʿ伺ÀÌ ÀÌ Ä¡·á ¿µ¿ªÀÇ Å« Á¡À¯À²À» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¾Ï ¿¬±¸´Â º¹ÀâÇϰí Ç¥ÀûÄ¡·áÁ¦, ¸é¿ªÄ¡·áÁ¦, º´¿ë¿ä¹ýÀÇ ½ÃÇèÀÌ ÇÊ¿äÇÕ´Ï´Ù. ±ÔÁ¦ ±â°üÀº ¾Ï Ä¡·áÁ¦ÀÇ ½ÂÀÎÀ» ¿ì¼±½ÃÇϱ⠶§¹®¿¡ ÀÌ ºÐ¾ßÀÇ ÀÓ»ó½ÃÇèÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¤¹ÐÀÇ·á¿Í ¹ÙÀÌ¿À¸¶Ä¿ ¿¬±¸ÀÇ ¹ßÀüÀ¸·Î ¾Ï ºÐ¾ß ÀÓ»ó½ÃÇèÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ȯÀÚ ¸ðÁý ¹× ÀÓ»ó½ÃÇè °ü¸® Àü¹® Áö½ÄÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. Á¦¾àȸ»ç, Á¤ºÎ±â°ü, ȯÀÚ´ÜüÀÇ °­·ÂÇÑ ÅõÀÚ´Â ¾Ï ¿¬±¸¸¦ ´õ¿í ÃËÁøÇϰí ÀÖÀ¸¸ç, ¾Ï ºÐ¾ß´Â ÀÓ»ó½ÃÇèÀÇ ÁÖ¿ä ºÎ¹®ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

"ÃÖÁ¾ »ç¿ëÀÚº°·Î´Â Á¦¾à ¹× ¹ÙÀÌ¿À Á¦¾à ±â¾÷ÀÌ ¿¹Ãø ±â°£ µ¿¾È ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀå¿¡¼­ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù."

ÀÓ»ó½ÃÇèÀ» ÀÚüÀûÀ¸·Î ¼öÇàÇϱâ À§Çؼ­´Â ÀÎÇÁ¶ó, ÀηÂ, ±ÔÁ¦ Áؼö¿¡ ¸¹Àº ÅõÀÚ°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ ÀÓ»ó½ÃÇèÀÇ º¹À⼺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾Æ¿ô¼Ò½ÌÀÌ º¸´Ù ºñ¿ë È¿À²ÀûÀ̰í È¿À²ÀûÀÎ ¼±ÅÃÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè ¼³°è, ȯÀÚ ¸ðÁý, ±ÔÁ¦ Áؼö, µ¥ÀÌÅÍ °ü¸® µîÀÇ Àü¹®¼ºÀ» Ȱ¿ëÇÏ¿© ÀǾàǰ °³¹ßÀ» °¡¼ÓÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, R&D ÆÄÀÌÇÁ¶óÀÎÀÇ È®´ë¿Í Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó Á¦¾à»çµéÀº ÀÓ»ó ¼­ºñ½º ¹× ÀÓ»ó½ÃÇèÀÇ ¾Æ¿ô¼Ò½ÌÀ» ÅëÇØ ¾÷¹« ºÎ´ãÀ» ÃÖ¼ÒÈ­ÇÏ°í ¸®¼Ò½º¸¦ ÃÖÀûÈ­Çϰí ÀÖ½À´Ï´Ù.

¼¼°èÀÇ ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ, °æÀï ±¸µµ, ÇâÈÄ µ¿Çâ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ÇÁ¸®¹Ì¾ö ÀλçÀÌÆ®

Á¦5Àå ½ÃÀå °³¿ä

Á¦6Àå ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀå : ¼­ºñ½º À¯Çüº°

Á¦7Àå ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀå : ´Ü°èº°

Á¦8Àå ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀå : ¸ð´Þ¸®Æ¼º°

Á¦9Àå ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀå : Ä¡·á ¿µ¿ªº°

Á¦10Àå ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀå : µô¸®¹ö¸® ¸ðµ¨º°

Á¦11Àå ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀå : ÀÓ»ó½ÃÇè µðÀÚÀκ°

Á¦12Àå ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦13Àå ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀå : Áö¿ªº°

Á¦14Àå °æÀï ±¸µµ

Á¦15Àå ±â¾÷ °³¿ä

Á¦16Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global clinical trial services market is projected to reach USD 101.86 billion in 2030 from USD 66.59 billion in 2025, growing at a CAGR of 8.9% during the forecast period. This market is expanding as pharmaceutical, biotechnology, and medical device companies are increasingly outsourcing their clinical research activities to Contract Research Organizations (CROs). Flexible service models, such as Functional Service Provider (FSP) and hybrid service delivery models, offered by CROs enable cost management while allowing companies to retain control over critical operations. There is a growing demand for patient-centric trials, leveraging decentralized models, wearable devices, and digital platforms to enhance patient participation and retention. Technological advancements, including artificial intelligence (AI) and real-world data (RWD), are optimizing trial efficiency, site selection, and patient recruitment. The rising demand for personalized and precision medicine is driving an increase in clinical studies focused on targeted therapies, requiring CROs to support complex trial designs. Regulatory bodies are emphasizing pediatric clinical trials, requiring CROs to develop specialized expertise. Additionally, FDA guidelines promoting diversity in clinical trials are creating opportunities for CROs to expand patient recruitment and ensure broader representation. The increasing pipeline of new drug modalities, including cell and gene therapies, biologics, and RNA-based treatments, is further driving the need for specialized clinical research services.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2024-2030
Units ConsideredValue (USD billion)
SegmentsPhase, Service Type, Therapeutic Area, Application,End User, and Region
Regions coveredNorth America, Europe, APAC, RoW

"The oncology therapy area segment held the largest share in the clinical trial services market, by therapy area, during the forecast period"

In 2024, the oncology therapy area held the largest market within the clinical trial services market by therapy area. Factors such as the large number of cancer cases worldwide and the need for new treatments are supporting the large share of this therapy area. Cancer research is complex, requiring trials for targeted therapies, immunotherapies, and combination treatments. Regulatory agencies prioritize cancer drug approvals, leading to more trials in this area. Advances in precision medicine and biomarker research have also increased oncology trials, requiring expertise in patient recruitment and trial management. Strong investments from pharmaceutical companies, government agencies, and patient organizations further drive cancer research, making oncology the leading segment in clinical trials.

"The pharmaceutical & biopharmaceutical companies end user segment held the largest market share in the clinical trials services market, by end user, during the forecast period"

Pharmaceutical and biopharmaceutical companies dominated the clinical trial services end-user/sponsor market during the forecast period. Conducting in-house trials demands substantial investments in infrastructure, personnel, and regulatory compliance, making outsourcing a more cost-effective and efficient alternative as trial complexity increases. Partnering with Contract Research Organizations (CROs) allows these companies to leverage expertise in trial design, patient recruitment, regulatory adherence, and data management, expediting drug development. Additionally, the expanding R&D pipeline and growing focus on precision medicine have led pharmaceutical companies to outsource clinical services and laboratory testing, minimizing operational burdens and optimizing resources.

"Asia Pacific: The fastest growing region in the clinical trial services market"

The Asia Pacific clinical trial services market is projected to register the highest growth rate during the forecast period. This high growth is attributed to its large patient pool, high incidence of chronic and infectious diseases, and growing focus on developing biologics, biosimilars, and advanced therapies. Global pharmaceutical companies are increasingly shifting manufacturing and clinical research to the region to benefit from cost advantages, regulatory improvements, and better patient retention in trials. Additionally, government support and increasing investments in clinical research have further driven the outsourcing of clinical trial activities to APAC, contributing to its strong market growth.

The primary interviews conducted for this report can be categorized as follows:

List of Companies Profiled in the Report:

Research Coverage:

This report provides a detailed picture of the global clinical trial service market. It aims to estimate the size and future growth potential of the market across different segments such as the service type, therapy area, phase, delivery model, modality, end user/sponsor, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the clinical trial services market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; partnerships, agreements, new service launches, mergers and acquisitions, and recent developments associated with the clinical trial services market. Competitive analysis of upcoming startups in the clinical trial services market ecosystem is covered in this report.

Reasons to buy this report :

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall clinical trial services market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE

7 CLINICAL TRIAL SERVICES MARKET, BY PHASE

8 CLINICAL TRIAL SERVICES MARKET, BY MODALITY

9 CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA

10 CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL

11 CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN

12 CLINICAL TRIAL SERVICES MARKET, BY END USER

13 CLINICAL TRIAL SERVICES MARKET, BY REGION

14 COMPETITIVE LANDSCAPE

15 COMPANY PROFILES

16 APPENDIX

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â